AdaptHealth
Refocusing on sleep and respiratory at scale, with capitation upside but execution and leverage risks
AdaptHealth is simplifying to a sleep and respiratory focused, scaled home medical equipment platform. In August 2026 it agreed to divest its Diabetes Health business to Cardinal Health for $235 million and reset full‑year 2026 guidance on a continuing‑operations basis.
Management also formed an e‑commerce joint venture combining The CPAP Shop with cpap.com to reach undiagnosed OSA patients through home sleep testing and a fully digital path to therapy.
These moves concentrate resources where AdaptHealth’s service density, payer relationships and digital tools can matter most, but they come alongside a steep near‑term profitability reset driven by a large West Coast capitated contract ramp, a manufacturer price hike, and stranded overhead that will take time to remove.
Financially, the company refinanced its bank debt in April 2026, drew a delayed‑draw term loan and redeemed its 6.125% senior notes due 2028, leaving senior notes due 2029 and 2030 outstanding. As of June 30, 2026, gross debt was about $1.89 billion and cash $43 million.
Free cash flow for the six months ended June 30, 2026 was negative $48 million due to front‑loaded patient equipment purchases to support capitated arrangements, while full‑year 2026 guidance calls for $80 to $120 million of FCF (including the to‑be‑divested Diabetes unit).
A July 2026 data breach that exfiltrated PHI and stored billing passwords adds reputational and regulatory risk. Overall we see a capable scale operator with recurring revenue characteristics, but with modest moat, limited pricing power under Medicare/commercial schedules, material leverage, and execution risk on capitation.
Does AdaptHealth have a strong competitive moat?
Moat sources assessed via five lenses with relative weights: Switching costs (30%), Cost advantages (25%), Intangible assets (20%), Efficient scale (15%), Network effects (10%). 1) Switching costs (score 60): resupply programs, prescription management, and payer steerage create some inertia, especially in sleep therapy and oxygen.
The platform serves ~4.8 million patients annually via ~670 locations, supporting embedded referral relationships.
Still, payors can rebid or redirect and patients can be reassigned, limiting durability. 2) Cost advantages (score 55): national purchasing and shared operations (billing, logistics, digital myAPP) yield unit-cost efficiencies, but June 2026 guidance explicitly cited a manufacturer price increase that AdaptHealth could not fully pass through, evidencing constrained bargaining power. 3) Intangible assets (score 55): accreditation, payor contracts, clinical know‑how, and a broad referral base matter, but there is little brand premium in a reimbursement‑driven DME category. 4) Efficient scale (score 50): local market density helps routing, set‑ups and service times; however, DME markets sustain multiple regional players and scale advantages are not insurmountable.
The capitation model with a major integrated delivery network can confer territory exclusivity, but execution complexity is high. 5) Network effects (score 30): limited; more patients do not inherently increase value for other users beyond modest data/operating leverage.
Weighted outcome is a single‑moat profile with execution and reimbursement risks that cap durability.
Does AdaptHealth have pricing power in its industry?
Revenue is predominantly rate‑set by Medicare/Medicaid and commercial contracts, limiting discretionary pricing. 2025 payor mix: Insurance ~$1.96B (61%), Government ~$0.85B (26%), Patient pay ~$0.43B (13%) on ~$3.24B total.
A cited H2 2026 supplier price increase and margin pressure from urgent‑order workflows under capitation underscore limited ability to reprice quickly. Divesting Diabetes (which saw margin headwinds from shift toward government payors) reduces one pressure point but does not change structural exposure to fee schedules and bidding cycles.
How predictable is AdaptHealth's business?
Recurring resupply and fixed‑rental revenue add predictability, and long‑term sleep/respiratory prevalence trends are supportive. Yet 2026 guidance was reset to net revenue of $2.85–$2.89B and Adjusted EBITDA of $490–$520M on continuing operations after divestiture effects, capitation ramp inefficiencies, and a supplier price increase.
Operational disruption shows that while the revenue base is recurring, margins can be volatile during transitions. Future DMEPOS fee schedule updates are inflation‑linked but competitive bidding may reintroduce category pricing pressure later in the decade.
Is AdaptHealth financially strong?
After the April 2026 refinancing, AdaptHealth entered a 2026 Credit Facility (term loan + delayed‑draw term loan + $450M revolver) and in August 2026 redeemed its 6.125% notes due 2028 using the delayed‑draw term loan.
As of June 30, 2026: secured term loan $325M, revolver $150M, senior unsecured notes $1.425B (4.625% due 2029; 5.125% due 2030), cash ~$43M; pro forma for the redemption, fixed‑rate notes are staggered into 2029/2030 and the bank debt matures in 2031 (with springing maturities tied to note balances).
Leverage and interest burden remain material, leaving limited cushion if EBITDA underperforms.
How effective is AdaptHealth's capital allocation strategy?
Track record mixes a transformational roll‑up (AeroCare 2021) with subsequent tuck‑ins and divestitures.
Recent decisions are directionally cleaner: sale of Diabetes Health to Cardinal Health; contribution of The CPAP Shop into a JV with cpap.com and telehealth to build a direct‑to‑consumer funnel; utilization of a delayed‑draw term loan to retire higher‑coupon notes; and workforce restructuring to remove ~$19M of annualized costs.
Offsetting risks: capitation ramp mis‑estimation created near‑term margin and cash drag; SBC remains present; and ongoing FCA/cyber exposures require cash for compliance.
Does AdaptHealth have high-quality management?
CEO Suzanne Foster (since May 2024) brings relevant home‑care and supply‑chain credentials (Cardinal Health At‑Home Solutions, Stanley Healthcare, Medtronic). Communication around the 2026 reset acknowledged inherited workflow issues on the large capitated contract and outlined cost actions and process fixes.
Governance baggage from past leadership has largely turned over, though the July 2026 cyber incident and recent securities settlement emphasize the need for continued rigor in controls and risk management.
Is AdaptHealth a quality company?
AdaptHealth is an average quality company with a quality score of 51/100
- Portfolio simplification: sale of Diabetes Health to Cardinal Health and an e‑commerce JV consolidate focus on sleep/respiratory while exiting lower‑margin and noncore lines.
- Capitation as growth vector: exclusive 5‑year HME deal with a major health system (>10 million members) and a new Humana OneHome arrangement add scale but pressured margins during ramp.
- Leverage remains elevated despite April 2026 refinancing and redemption of 2028 notes; liquidity adequate but interest and covenant headroom require disciplined execution.
- TTM FCF through Q2‑26 approximates $98 million after heavy H1 equipment capex; management now guides to $80–$120 million FCF for 2026 as it rightsizes costs.
- Cybersecurity incident in June/July 2026 and a $35 million securities settlement create additional legal/reputation overhangs.
What is the fair value of AdaptHealth stock?
Is AdaptHealth a good investment at $5.87?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.